Influence of Human Cerebrospinal Fluid on Blood Coagulation in Vitro

1965 ◽  
Vol 13 (6) ◽  
pp. 615-620 ◽  
Author(s):  
D. DeVIVO ◽  
E. KLINE ◽  
P. R. DODGE
Keyword(s):  
Cerebrospinal Fluid ◽  
Blood Coagulation ◽  
Human Cerebrospinal Fluid

scholarly journals Human Cerebrospinal Fluid Apolipoprotein E Isoforms are Apparently Inefficient at Complexing with Synthetic Alzheimer’s Amyloid-β Peptide (Aß1−40) in vitro

2002 ◽  
Vol 8 (7) ◽  
pp. 376-381 ◽  
Author(s):  
Zhongmin Zhou ◽  
Norman Relkin ◽  
Jorge Ghiso ◽  
Jonathan D. Smith ◽  
Sam Gandy
Keyword(s):  
Cerebrospinal Fluid ◽  
Apolipoprotein E ◽  
Amyloid Β ◽  
Amyloid Β Peptide ◽  
Human Cerebrospinal Fluid

scholarly journals Bactericidal Activity of Vancomycin in Cerebrospinal Fluid

1999 ◽  
Vol 43 (8) ◽  
pp. 1932-1934 ◽  
Author(s):  
Markus Nagl ◽  
Claudia Neher ◽  
Josef Hager ◽  
Bettina Pfausler ◽  
Erich Schmutzhard ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Staphylococcus Epidermidis ◽  
Once Daily ◽  
Human Cerebrospinal Fluid ◽  
Viable Bacteria ◽  
High Concentrations ◽  
Time Kill ◽  
Support Time

ABSTRACT Intraventricular application of vancomycin is an effective therapeutic regimen for the treatment of shunt-associated staphylococcal ventriculitis. We examined the in vitro activity of vancomycin at high concentrations against Staphylococcus aureus ATCC 25923 and Staphylococcus epidermidis ATCC 12228 in human cerebrospinal fluid samples. Time-kill curves revealed equal efficacies for concentrations of 10, 100, and 300 μg/ml, and incubation times of 24 to 48 h were needed to achieve a 3 log10 reduction of viable bacteria. A concentration of 5 μg/ml showed a slightly lower activity, but this difference was not significant. In an infant who was successfully treated for shunt-associated ventriculitis due to S. epidermidis by once-daily local administration of vancomycin (3 mg for 2 days and 5 mg for 4 days [0.5 to 0.8 mg/kg of body weight]) the in vivo kill kinetics were similar to those for the in vitro results. These results support time-dose regimens that provide trough vancomycin levels of 5 to 10 μg/ml.

Amyloid β binding proteins in vitro and in normal human cerebrospinal fluid

1995 ◽  
Vol 191 (1-2) ◽  
pp. 79-82 ◽  
Author(s):  
Adam Golabek ◽  
Marcos A. Marques ◽  
Maciej Lalowski ◽  
Thomas Wisniewski
Keyword(s):  
Cerebrospinal Fluid ◽  
Binding Proteins ◽  
Amyloid Β ◽  
Human Cerebrospinal Fluid ◽  
Normal Human

scholarly journals Validation and assessment of preanalytical factors of a fluorometric in vitro assay for glucocerebrosidase activity in human cerebrospinal fluid

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Linn Oftedal ◽  
Jodi Maple-Grødem ◽  
Marthe Gurine Gunnarsdatter Førland ◽  
Guido Alves ◽  
Johannes Lange
Keyword(s):  
Cerebrospinal Fluid ◽  
Enzymatic Activity ◽  
Lewy Bodies ◽  
Activity Assay ◽  
Limit Of Quantification ◽  
Gene Encoding ◽  
Vitro Assay ◽  
Freeze Thaw ◽  
Human Cerebrospinal Fluid

AbstractLysosomal dysfunction is an emerging feature in the pathology of Parkinson’s disease and Dementia with Lewy bodies. Mutations in the GBA gene, encoding the enzyme Glucocerebrosidase (GCase), have been identified as a genetic risk factor for these synucleinopathies. As a result, there has been a growing interest in the involvement of GCase in these diseases. This GCase activity assay is based on the catalytic hydrolysis of 4-methylumbelliferyl β-d-glucopyranoside that releases the highly fluorescent 4-methylumbelliferyl (4-MU). The final assay protocol was tested for the following parameters: Lower limit of quantification (LLOQ), precision, parallelism, linearity, spike recovery, number of freeze–thaw events, and sample handling stability. The GCase activity assay is within acceptable criteria for parallelism, precision and spike recovery. The LLOQ of this assay corresponds to an enzymatic activity of generating 0.26 pmol 4-MU/min/ml. The enzymatic activity was stable when samples were processed and frozen at − 80 °C within 4 h after the lumbar puncture procedure. Repetitive freeze–thaw events significantly decreased enzyme activity. We present the validation of an optimized in vitro GCase activity assay, based on commercially available components, to quantify its enzymatic activity in human cerebrospinal fluid and the assessment of preanalytical factors.

Release of alpha-melanocyte stimulating hormone into rat and human cerebrospinal fluid in vivo and from rat hypothalamus slices in vitro

Peptides ◽  
1981 ◽  
Vol 2 (1) ◽  
pp. 93-100 ◽  
Author(s):  
T.L. O'Donohue ◽  
C.G. Charlton ◽  
N.B. Thoa ◽  
C.J. Helke ◽  
T.W. Moody ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Rat Hypothalamus ◽  
Melanocyte Stimulating Hormone ◽  
Human Cerebrospinal Fluid ◽  
Stimulating Hormone

scholarly journals Corrigendum: Human Cerebrospinal Fluid Promotes Neuronal Viability and Activity of Hippocampal Neuronal Circuits In Vitro

2016 ◽  
Vol 10 ◽  
Author(s):  
Marta Perez-Alcazar ◽  
Georgia Culley ◽  
Tim Lyckenvik ◽  
Kristoffer Mobarrez ◽  
Andreas Björefeldt ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Neuronal Circuits ◽  
Neuronal Viability ◽  
Human Cerebrospinal Fluid

scholarly journals Human cerebrospinal fluid promotes spontaneous gamma oscillations in the hippocampus in vitro

Hippocampus ◽  
2019 ◽  
Vol 30 (2) ◽  
pp. 101-113 ◽  
Author(s):  
Andreas Bjorefeldt ◽  
Firoz Roshan ◽  
My Forsberg ◽  
Henrik Zetterberg ◽  
Eric Hanse ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Gamma Oscillations ◽  
Human Cerebrospinal Fluid

scholarly journals Effects of Anesthetic Isoflurane and Desflurane on Human Cerebrospinal Fluid Aβ and τ Level

2013 ◽  
Vol 119 (1) ◽  
pp. 52-60 ◽  
Author(s):  
Bin Zhang ◽  
Ming Tian ◽  
Hui Zheng ◽  
Yu Zhen ◽  
Yun Yue ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Alzheimer Disease ◽  
Spinal Anesthesia ◽  
Amyloid Protein ◽  
Total Tau ◽  
Human Cerebrospinal Fluid ◽  
Csf Levels ◽  
Β Amyloid ◽  
Spinal Catheter

Abstract Background: Accumulation of β-amyloid protein (Aβ) and tau protein is the main feature of Alzheimer disease neuropathogenesis. Anesthetic isoflurane, but not desflurane, may increase Aβ levels in vitro and in animals. Therefore, we set out to determine the effects of isoflurane and desflurane on cerebrospinal fluid (CSF) levels of Aβ and tau in humans. Methods: The participants were assigned into spinal anesthesia (N = 35), spinal plus desflurane anesthesia (N = 33), or spinal plus isoflurane anesthesia (N = 38) group by randomization using computer-generated lists. Pre- and postoperative human CSF samples were obtained through an inserted spinal catheter. The levels of Aβ (Aβ40 and Aβ42) and total tau in the CSF were determined. Results: Here, we show that isoflurane, but not desflurane, was associated with an increase in human CSF Aβ40 levels (from 10.90 to 12.41 ng/ml) 24 h after the surgery under anesthesia compared to spinal anesthesia (from 11.59 to 11.08 ng/ml), P = 0.022. Desflurane, but not isoflurane, was associated with a decrease in Aβ42 levels 2 h after the surgery under anesthesia (from 0.39 to 0.35 ng/ml) compared to spinal anesthesia (from 0.43 to 0.44 ng/ml), P = 0.006. Isoflurane and desflurane did not significantly affect the tau levels in human CSF. Conclusions: These studies have established a system to study the effects of anesthetics on human biomarkers associated with Alzheimer disease and cognitive dysfunction. These findings have suggested that isoflurane and desflurane may have different effects on human CSF Aβ levels.

Sign in / Sign up

Export Citation Format

Share Document